AIMS: The clinical significance of chemokine receptor CCR7 expression in pancreatic ductal cancer was investigated. METHODS: Immunohistochemical staining of 89 pancreatic cancers treated macroscopically with curative resection without hematogenous metastases or peritoneal dissemination were analyzed in association with clinicopathological data. RESULTS: The positivity of CCR7 in pancreatic cancer was 32.6% (29/89). A significant correlation was detected between CCR7-positive expression and lymph node metastasis. Patients with CCR7-positive tumors had significantly shorter survival times than those with CCR7-negative tumors (median, 12.8 vs. 21.9 months, respectively; p = 0.0039). CCR7 expression was an independent prognostic factor (hazard ratio, 1.949; p = 0.0364) by multivariate survival analysis; however, it was not an indicator for any particular site of recurrence. CONCLUSION: The survival impact of CCR7 expression on resectable pancreatic cancer may be associated with lymphatic spread. The results from the present study should foster further investigation of treatments using an inhibitor for the CCR7 protein to improve the survival of pancreatic cancer. Copyright 2008 S. Karger AG, Basel.
AIMS: The clinical significance of chemokine receptor CCR7 expression in pancreatic ductal cancer was investigated. METHODS: Immunohistochemical staining of 89 pancreatic cancers treated macroscopically with curative resection without hematogenous metastases or peritoneal dissemination were analyzed in association with clinicopathological data. RESULTS: The positivity of CCR7 in pancreatic cancer was 32.6% (29/89). A significant correlation was detected between CCR7-positive expression and lymph node metastasis. Patients with CCR7-positive tumors had significantly shorter survival times than those with CCR7-negative tumors (median, 12.8 vs. 21.9 months, respectively; p = 0.0039). CCR7 expression was an independent prognostic factor (hazard ratio, 1.949; p = 0.0364) by multivariate survival analysis; however, it was not an indicator for any particular site of recurrence. CONCLUSION: The survival impact of CCR7 expression on resectable pancreatic cancer may be associated with lymphatic spread. The results from the present study should foster further investigation of treatments using an inhibitor for the CCR7 protein to improve the survival of pancreatic cancer. Copyright 2008 S. Karger AG, Basel.
Authors: Helenisa Helena Oliveira-Neto; Pedro Paulo Chaves de Souza; Márcio Roberto Barbosa da Silva; Elismauro Francisco Mendonça; Tarcília Aparecida Silva; Aline Carvalho Batista Journal: Tumour Biol Date: 2012-09-14
Authors: Jesse Gore; Imade E Imasuen-Williams; Abass M Conteh; Kelly E Craven; Monica Cheng; Murray Korc Journal: Cancer Lett Date: 2016-06-03 Impact factor: 8.679